ESC 365
Menu
Home
Search
Events
About
ESC Platforms
Escardio.org
ESC 365
ESC eLearning
Create an account
Sign in
Back
ESC Premium Access
Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes
Session:
Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes
Topic:
Risk Factors and Prevention
Speaker:
Professor G. De Ferrari (Turin, IT)
Sponsored by Sanofi and Regeneron
Event:
ESC Congress 2019
Congress Presentation
Sign in for access options
Sign in for access options
About the speaker
Professor Gaetano Maria De Ferrari
Hospital Molinette of the University Hospital S. Giovanni Battista, Turin (Italy)
18
presentations
0
follower
Access the full session
Implications of new CV risk reduction indication of PCSK9 inhibitors - Focus on ODYSSEY outcomes
Speakers:
Professor G. De Ferrari
Access
About the event
ESC Congress 2019
31 August - 4 September 2019
Sessions
Presentations
ESC 365 is supported by
Explore sponsored resources